CD73: Friend or Foe in Lung Injury.
CD73
adenosine
inflammatory response
lung injury
purinergic receptor
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
29
01
2023
revised:
09
03
2023
accepted:
10
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Ecto-5'-nucleotidase (CD73) plays a strategic role in calibrating the magnitude and chemical nature of purinergic signals that are delivered to immune cells. Its primary function is to convert extracellular ATP to adenosine in concert with ectonucleoside triphosphate diphosphohydrolase-1 (CD39) in normal tissues to limit an excessive immune response in many pathophysiological events, such as lung injury induced by a variety of contributing factors. Multiple lines of evidence suggest that the location of CD73, in proximity to adenosine receptor subtypes, indirectly determines its positive or negative effect in a variety of organs and tissues and that its action is affected by the transfer of nucleoside to subtype-specific adenosine receptors. Nonetheless, the bidirectional nature of CD73 as an emerging immune checkpoint in the pathogenesis of lung injury is still unknown. In this review, we explore the relationship between CD73 and the onset and progression of lung injury, highlighting the potential value of this molecule as a drug target for the treatment of pulmonary disease.
Identifiants
pubmed: 36982618
pii: ijms24065545
doi: 10.3390/ijms24065545
pmc: PMC10056814
pii:
doi:
Substances chimiques
5'-Nucleotidase
EC 3.1.3.5
Adenosine
K72T3FS567
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82104491
Organisme : Natural Science Foundation of Sichuan
ID : 2023NSFSC0674
Organisme : Natural Science Foundation of Sichuan
ID : 2022NSFSC0854
Organisme : Postdoctoral Science Foundation of China
ID : 2021M693789
Références
Mediators Inflamm. 2014;2014:254640
pubmed: 25210228
Br J Pharmacol. 1992 Aug;106(4):774-82
pubmed: 1327386
Crit Care. 2021 Dec 19;25(1):440
pubmed: 34924022
Sci Rep. 2021 Jun 16;11(1):12727
pubmed: 34135424
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
Immunol Rev. 1998 Feb;161:95-109
pubmed: 9553767
Am J Physiol Lung Cell Mol Physiol. 2021 Jan 1;320(1):L12-L16
pubmed: 33050737
Stem Cell Reports. 2018 Apr 10;10(4):1412-1425
pubmed: 29551673
Front Physiol. 2021 Jan 28;12:614330
pubmed: 33584346
J Cell Biol. 1997 Jan 27;136(2):421-31
pubmed: 9015312
Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(1):H190-H200
pubmed: 31050560
Lancet Respir Med. 2014 Feb;2(2):98-107
pubmed: 24503265
J Immunol. 2013 Oct 15;191(8):4165-73
pubmed: 24043904
Am J Physiol Cell Physiol. 2019 Dec 1;317(6):C1079-C1092
pubmed: 31461341
Trends Immunol. 2012 May;33(5):231-7
pubmed: 22487321
Front Immunol. 2019 Jul 16;10:1633
pubmed: 31379836
Int J Mol Sci. 2021 May 14;22(10):
pubmed: 34068999
Trends Cancer. 2016 Feb 1;2(2):95-109
pubmed: 27014745
JCI Insight. 2022 Feb 8;7(3):
pubmed: 35132961
Blood. 2011 Apr 21;117(16):4387-93
pubmed: 21346249
Regen Ther. 2019 Aug 24;11:207-211
pubmed: 31489344
J Med Chem. 2015 Aug 13;58(15):6248-63
pubmed: 26147331
ACS Med Chem Lett. 2020 Sep 03;11(11):2253-2260
pubmed: 33214837
Clin Cancer Res. 2013 Oct 15;19(20):5626-35
pubmed: 23983257
FASEB J. 2023 Jan;37(1):e22684
pubmed: 36468677
Biochim Biophys Acta Gen Subj. 2021 May;1865(5):129842
pubmed: 33434633
Cancer Immunol Immunother. 2021 Jul;70(7):1965-1976
pubmed: 33416944
Eur J Pharmacol. 2013 Aug 15;714(1-3):522-5
pubmed: 23850943
Cell. 2018 Nov 1;175(4):1156-1167.e15
pubmed: 30270040
Int J Mol Sci. 2019 Feb 28;20(5):
pubmed: 30823477
J Immunother Cancer. 2018 Dec 4;6(1):136
pubmed: 30514403
Curr Opin Oncol. 2001 Jul;13(4):218-23
pubmed: 11429477
Mol Cancer Ther. 2022 Jun 1;21(6):948-959
pubmed: 35405741
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52
pubmed: 20080644
J Biol Chem. 2003 Apr 11;278(15):13468-79
pubmed: 12560324
Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):339-348
pubmed: 30676071
Oncoimmunology. 2013 Sep 1;2(9):e26246
pubmed: 24319640
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32530438
Cancer Immunol Res. 2020 Aug;8(8):1064-1074
pubmed: 32381524
Nat Rev Rheumatol. 2017 Jan;13(1):41-51
pubmed: 27829671
Chembiochem. 2012 Nov 5;13(16):2384-91
pubmed: 22997138
Nat Immunol. 2017 Dec;18(12):1332-1341
pubmed: 29083399
Life Sci. 2020 Oct 15;259:118389
pubmed: 32898522
Pediatr Res. 2017 Aug 23;:
pubmed: 28832580
J Virol. 2020 Nov 23;94(24):
pubmed: 32967958
J Immunol. 1989 Sep 15;143(6):1815-21
pubmed: 2550543
Biochem Pharmacol. 2021 May;187:114322
pubmed: 33161020
Nat Commun. 2021 May 5;12(1):2540
pubmed: 33953163
J Infect Dis. 2019 Feb 23;219(6):964-974
pubmed: 30307561
Reprod Sci. 2020 Aug;27(8):1627-1636
pubmed: 32430714
Clin Chest Med. 2020 Mar;41(1):25-38
pubmed: 32008627
Mol Cell Biochem. 2021 Aug;476(8):2891-2898
pubmed: 33740184
Sci Rep. 2021 Mar 16;11(1):6035
pubmed: 33727591
J Clin Invest. 2020 Mar 2;130(3):1185-1198
pubmed: 31770109
Int J Cancer. 2014 Mar 15;134(6):1466-73
pubmed: 23982901
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34253638
Circulation. 2016 Aug 2;134(5):405-21
pubmed: 27482003
Front Immunol. 2020 Oct 02;11:02168
pubmed: 33123122
Cancer Res. 2022 Nov 2;82(21):4079-4092
pubmed: 36066413
Pediatr Res. 2020 Jun;87(7):1201-1210
pubmed: 31835269
Int J Mol Sci. 2020 Mar 26;21(7):
pubmed: 32225110
J Clin Invest. 2021 Jun 1;131(11):
pubmed: 34060477
JAMA. 2020 Feb 25;323(8):725-733
pubmed: 32065831
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1485-97
pubmed: 11350744
Pharmacol Res. 2015 Oct;100:85-92
pubmed: 26241177
Nat Rev Cancer. 2017 Dec;17(12):709-724
pubmed: 29059149
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629
pubmed: 32514148
Cancers (Basel). 2021 Apr 27;13(9):
pubmed: 33925516
J Leukoc Biol. 2020 Sep;108(3):867-882
pubmed: 32017200
J Exp Med. 2004 Dec 6;200(11):1395-405
pubmed: 15583013
Purinergic Signal. 2021 Mar;17(1):117-125
pubmed: 33336318
Clin Transl Med. 2018 Jun 22;7(1):19
pubmed: 29931538
Cancer Lett. 2022 Jul 10;538:215697
pubmed: 35487310
Cancer Res. 2016 May 15;76(10):3045-56
pubmed: 26921334
Oncoimmunology. 2021 Jul 8;10(1):1940675
pubmed: 34290905
Front Pharmacol. 2020 Nov 30;11:589343
pubmed: 33328996
J Immunol. 2007 Jun 15;178(12):8127-37
pubmed: 17548651
J Neuroinflammation. 2017 May 10;14(1):102
pubmed: 28486969
FASEB J. 2017 Jul;31(7):2869-2880
pubmed: 28325757
Am J Chin Med. 2021;49(3):661-676
pubmed: 33683190
Front Pharmacol. 2017 Sep 25;8:661
pubmed: 28993732
PLoS Pathog. 2015 Aug 27;11(8):e1005126
pubmed: 26313746
Clin Lung Cancer. 2022 Mar;23(2):e140-e147
pubmed: 34393062
Cell. 2015 Feb 26;160(5):816-827
pubmed: 25723161
Br J Pharmacol. 2008 Mar;153 Suppl 1:S446-56
pubmed: 18311158
Clin Transl Med. 2021 Jan;11(1):e269
pubmed: 33463071
Med Hypotheses. 2020 Oct;143:109857
pubmed: 32464493
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Purinergic Signal. 2006 Jun;2(2):343-50
pubmed: 18404474
Biochem Pharmacol. 2021 May;187:114319
pubmed: 33161021
Circ Res. 2004 Oct 15;95(8):814-21
pubmed: 15358667
Cancer Res. 2011 Apr 15;71(8):2892-900
pubmed: 21292811
Brain. 2019 Mar 1;142(3):700-718
pubmed: 30689733
Acta Biochim Pol. 2012;59(4):647-52
pubmed: 23162807
Clin Cancer Res. 2020 Apr 15;26(8):2037-2046
pubmed: 31937613
Biochim Biophys Acta. 2008 May;1783(5):673-94
pubmed: 18302942
Eur J Immunol. 2011 May;41(5):1231-41
pubmed: 21469131
Am J Respir Crit Care Med. 2003 Jan 15;167(2):171-9
pubmed: 12406830
Cell Death Dis. 2020 Mar 23;11(3):202
pubmed: 32205841
Purinergic Signal. 2006 Jun;2(2):351-60
pubmed: 18404475
Radiother Oncol. 2010 Oct;97(1):149-61
pubmed: 20888056
Biochem J. 1938 Mar;32(3):597-601
pubmed: 16746659
Int J Mol Sci. 2022 Sep 13;23(18):
pubmed: 36142499
Front Med (Lausanne). 2021 Mar 09;8:606678
pubmed: 33768102
Biomolecules. 2022 May 13;12(5):
pubmed: 35625624
Front Genet. 2021 Nov 17;12:728200
pubmed: 34868205
Front Immunol. 2019 Apr 05;10:698
pubmed: 31024543
Eur J Immunol. 2007 Dec;37(12):3334-8
pubmed: 18034430
BMC Cancer. 2020 May 12;20(1):411
pubmed: 32397971
J Virol. 2014 Sep 1;88(17):10214-27
pubmed: 24965449
Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L794-L809
pubmed: 32726135
Front Pharmacol. 2017 Jan 13;7:525
pubmed: 28133450
Cancer Res. 2018 Feb 15;78(4):1003-1016
pubmed: 29229601
Immunobiology. 2022 Nov;227(6):152284
pubmed: 36191584
Mediators Inflamm. 2015;2015:460610
pubmed: 25691808
Intensive Care Med. 2020 Oct;46(10):1937-1940
pubmed: 32430515
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906